Ebos, John M. L.

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology

Angiogenesis and VEGF in CancerCancer Cells and Metastasis

Cited by 685

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy

Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research

Angiogenesis and VEGF in CancerCancer Cells and Metastasis

Cited by 291

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

Mutsaers, A. J., Francia, G., Man, S., Lee, C. R., Ebos, J. M. L., Wu, Y., Witte, L., Berry, S., Moore, M., & Kerbel, R. S. (2009) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 34

A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal

Mastri, M., Tracz, A., Lee, C. R., Dolan, M., Attwood, K., Christensen, J. G., Liu, S., & Ebos, J. M. L. (2018) · Cell Reports

Angiogenesis and VEGF in CancerTelomeres, Telomerase, and Senescence

Cited by 28